Abstract:Head and neck squamous cell carcinoma (HNSCC) is a type of head and neck cancer that is aggressive, difficult to treat, and often associated with poor prognosis. HNSCC is the sixth most common cancer worldwide, highlighting the need to develop novel treatments for this disease. The current standard of care for HNSCC usually involves a combination of surgical resection, radiation therapy, and chemotherapy. Chemotherapy is notorious for its detrimental side effects including nausea, fatigue, hair loss, and more. Radiation therapy can be a challenge due to the anatomy of the head and neck area and presence of normal tissues. In addition to the drawbacks of chemotherapy and radiation therapy, high morbidity and mortality rates for HNSCC highlight the urgent need for alternative treatment options. Immunotherapy has recently emerged as a possible treatment option for cancers including HNSCC, in which monoclonal antibodies are used to help the immune system fight disease. Combining monoclonal antibodies approved by the US Food and Drug Administration, such as cetuximab and pembrolizumab, with radiotherapy or platinum-based chemotherapy for patients with locally advanced, recurrent, or metastatic HNSCC is an accepted first-line therapy. Targeted radionuclide therapy can potentially be used in conjunction with the first-line therapy, or as an additional treatment option, to improve patient outcomes and quality of life. Epidermal growth factor receptor is a known molecular target for HNSCC; however, other targets such as human epidermal growth factor receptor 2, human epidermal growth factor receptor 3, programmed cell death protein 1, and programmed death-ligand 1 are emerging molecular targets for the diagnosis and treatment of HNSCC. To develop successful radiopharmaceuticals, it is imperative to first understand the molecular biology of the disease of interest. For cancer, this understanding often means detection and characterization of molecular targets, such as cell surface receptors, that can be used as sensitive targeting agents. The goal of this review article is to explore molecular targets for HNSCC and dissect previously conducted research in nuclear medicine and provide a possible path forward for the development of novel radiopharmaceuticals used in targeted radionuclide therapy for HNSCC, which has been underexplored to date.

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

Advances in Nonsurgical Treatment of Head and Neck Squamous Cell Carcinoma

Nanoparticle-Based Targeted Therapeutics In Head-And-Neck Cancer

New Advances in the Therapeutic Strategy of Head and Neck Squamous Cell Carcinoma: A Review of Latest Therapies and Cutting-Edge Research

Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

Emerging tyrosine kinase inhibitors for head and neck cancer

The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy

Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma

Clinical update on head and neck cancer: molecular biology and ongoing challenges

Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas

Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review

Current trends of targeted therapy for oral squamous cell carcinoma

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma

Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma

Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma

The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment

Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects

Novel Predictive Biomarkers in the Head and Neck Squamous Cell Carcinoma (HNSCC)